A Phase I Clinical Study to Evaluate the Pharmacokinetic Profile and Safety of Lanifibranor After Single Dose and Multiple Doses in Healthy Adult Chinese Subjects
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Lanifibranor (Primary)
- Indications Fibrosis; Liver cirrhosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 29 Dec 2023 Status changed from active, no longer recruiting to completed.
- 07 Nov 2023 Status changed from planning to active, no longer recruiting.
- 31 May 2023 New trial record